Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Effect of simvastatin on Lp(a) concentrations

S Haffner1, T Orchard, E Stein

  • 1Department of Medicine, University of Texas Health Science Center at San Antonio, USA.

Clinical Cardiology
|May 1, 1995
PubMed
Summary

This large clinical trial found that simvastatin, a common cholesterol-lowering drug, does not change lipoprotein(a) [Lp(a)] levels. However, simvastatin effectively reduces low-density lipoprotein (LDL) cholesterol, offering significant cardiovascular benefits.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions.

The American journal of pathology·1995
Same author

[Placental site trophoblastic tumor. Morphology, differential diagnosis and prognosis].

Der Pathologe·1995
Same author

Retinal vascular hamartoma in von Hippel-Lindau disease.

Archives of ophthalmology (Chicago, Ill. : 1960)·1995
Same author

Dosimetry of iodine-123-epidepride: a dopamine D2 receptor ligand.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·1995
Same author

The use of CD31 and collagen IV as vascular markers. A study of 56 vascular lesions.

Pathology, research and practice·1995
Same author

[Fatigue fractures of the sacrum in primary biliary liver cirrhosis].

Aktuelle Radiologie·1995

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • The impact of HMG-CoA reductase inhibitors on lipoprotein(a) [Lp(a)] levels is debated, with conflicting findings in prior research.
  • Previous studies were often limited by small sample sizes and non-prospective designs, necessitating further investigation.

Purpose of the Study:

  • To prospectively evaluate the effect of simvastatin on Lp(a) concentrations in a large, randomized, controlled clinical trial.
  • To assess the efficacy of different simvastatin dosages and administration timings on Lp(a) and low-density lipoprotein (LDL) cholesterol levels.

Main Methods:

  • A 24-week prospective, randomized, controlled trial involving 343 subjects across 28 US clinical sites.
  • Participants received one of four treatments: placebo, simvastatin 10 mg QPM, simvastatin 20 mg QAM, or simvastatin 20 mg QPM.

Related Experiment Videos

  • Lp(a) concentrations, LDL cholesterol levels, and other relevant factors were monitored.

    • Main Results:

    • Simvastatin treatment was not associated with any significant change in Lp(a) concentrations compared to placebo.
    • These findings remained consistent regardless of race, baseline Lp(a) levels, or urinary albumin excretion.
    • Simvastatin demonstrated significant reductions in LDL cholesterol across all tested dosages and regimens (p < 0.001).

    Conclusions:

    • In a large-scale, randomized controlled trial, simvastatin does not alter Lp(a) levels.
    • Simvastatin effectively lowers LDL cholesterol, indicating its continued utility in lipid management.
    • The study clarifies the controversial role of statins concerning Lp(a) levels.